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Abstract
L-Aspartate a-decarboxylase (ADC) belongs to a class of pyruvoyl dependent enzymes and catalyzes the conversion of
aspartate to b-alanine in the pantothenate pathway, which is critical for the growth of several micro-organisms, including
Mycobacterium tuberculosis (Mtb). Its presence only in micro-organisms, fungi and plants and its absence in animals,
particularly human, make it a promising drug target. We have followed a chemoinformatics-based approach to identify
potential drug-like inhibitors against Mycobacterium tuberculosis L-aspartate a-decarboxylase (MtbADC). The structure-
based high throughput virtual screening (HTVS) mode of the Glide program was used to screen 333,761 molecules of the
Maybridge, National Cancer Institute (NCI) and Food and Drug Administration (FDA) approved drugs databases. Ligands
were rejected if they cross-reacted with S-adenosylmethionine (SAM) decarboxylase, a human pyruvoyl dependent enzyme.
The lead molecules were further analyzed for physicochemical and pharmacokinetic parameters, based on Lipinski’s rule of
five, and ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. This analysis resulted in eight
small potential drug-like inhibitors that are in agreement with the binding poses of the crystallographic ADC:fumarate and
ADC:isoasparagine complex structures and whose backbone scaffolds seem to be suitable for further experimental studies
in therapeutic development against tuberculosis.
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Introduction
L-Aspartate a-alpha decarboxylase (ADC, EC 4.1.1.11),
encoded by the panD gene, is a lyase and catalyzes the
decarboxylation of aspartate to b-alanine, which is essential for
D-pantothenate formation (Fig. S1). Mutants of the panD gene are
defective in b-alanine biosynthesis [1]. b-alanine and D-pantoate
condense to form pantothenate, a precursor of coenzyme A (CoA),
which functions as an acyl carrier in fatty acid metabolism and
provides the 49-phosphopantetheine prosthetic group in fatty acid
biosynthesis, an essential need for the growth of several micro-
organisms, including Mycobacterium tuberculosis (Mtb) [2,3], the
causative bacterial agent of tuberculosis (Tb) [4].
The distinctive lipid rich cell wall of Mtb is responsible for the
unusually low permeability, virulence and resistance to therapeutic
agents [5,6]. At the heart of the fight against tuberculosis lies its
cell wall, a multilayered structure adorned with a number of lipo-
glycans that protect the bacterium in antimicrobial defense against
environmental stresses and treatment. Consequently, the metab-
olism and biosynthesis of lipids and lipo-glycans play a pivotal role
in the intracellular survival and persistence of Mtb. Any
impediment in the pantothenate pathway will therefore affect
the survival of the bacterium. As Mtb is notorious to develop
resistance towards drugs, progress in the treatment of tuberculosis
will require us to identify new targets in pathways critical for the
sustenance of Mtb, and to develop new drugs selectively inhibiting
these targets so as to minimize drug resistance and potential side
effects [7,8]. Since pantothenate is synthesized only in microor-
ganisms, fungi and plants, but not in humans, the enzymes that are
involved in this biosynthetic pathway qualify to be potential targets
for antibacterial and antifungal agents [9]. The absence of this
pathway in humans ensures that any inhibitor or drug against
ADC would have low toxicity in patients. In particular, the chance
of side effects in a long term treatment procedure will be minimal.
Moreover, the presence of the ADC gene in only one copy in the
Mtb genome further enhances its importance as a suitable drug
target.
MtbADC is translated as an unprocessed proenzyme (p-
protein). It undergoes autocatalyzed cleavage between Gly24
and Ser25, where the serine is modified to a pyruvoyl group,
resulting in the formation of 2.8 kDa b-chain and 11 kDa a-chain
containing the N-terminal pyruvoyl group. This processed a form
is necessary for the conversion of aspartate to b-alanine [10] and
the mutation S25A makes the protein uncleavable and inactive
[11]. So far, crystal structures have been determined for
unprocessed (uncleaved) ADC from E. coli (PDB id: 1PPY) [12],
Mtb (2C45) [13], and processed ADC from E. coli (1AW8) [14],
Francisella tularensis (3OUG), Campylobacter jejuni (3PLX), Thermus
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substrate analog fumarate (2EEO), Helicobacter pylori ADC
(HpyADC) (1UHD) [15] and HpyADC, complexed with substrate
analog isoasparagine (1UHE) [15]. The ADC protein folds into a
double-yb -barrel structure. It forms a homotetramer [13] and the
active site is shown to be at the interface of a dimer of processed
ADC [15].
The unique feature of being absent in human, in addition to its
significance in the cellular metabolism of Mtb, endows exclusive
significance upon ADC as an important drug and vaccine target.
Jacobs and coworkers [16] constructed a double deletion mutant
(DpanCD) with a view to globally impair the ability of Mtb to
synthesize lipids. Mice infected with the DpanCD mutant were able
to survive 22 weeks longer than those infected with the bacille
Calmette-Guerin-Pasteur (BCG-P) strain. Deletion of the genes
significantly attenuates Mtb and protects infected animals against
tuberculosis.
In an effort to discover inhibitors against ADC, b-hydroxyas-
partate, L-cysteic acid, D-serine, oxaloacetate and succinic
dehydrazine are reported as competitive inhibitors of ADC with
Ki of 0.13, 0.08, 0.16, 0.81, 0.73 mM, respectively [17,18,19] and
phenylhydrazine binds to the pyruvoyl group to inactivate the
protein [17]. While D-serine, b-hydroxyaspartate, and L-cysteic
acid interfere in vivo with the synthesis of pantothenic acid in
bacteria, external supply of aspartic acid, b-alanine, or pantothe-
nic acid can reverse their growth inhibitory action in E. coli
[20,21]. As these molecules do not have suitable pharmacochem-
ical and pharmacokinetic properties (unpublished data), recent
studies have emphasized the need to discover novel selective drug-
like inhibitors against MtbADC [13,22]. However, to date no
selective drug-like inhibitor against MtbADC has been reported.
To our knowledge, this is the first chemoinformatics-based drug
design approach to propose novel and selective inhibitors of
MtbADC.
Materials and Methods
Preparation of the processed MtbADC structure
Structural alignment of unprocessed and processed E. coli ADC
structures [12] by the use of Multiprot [23] shows a root mean
square deviation (RMSD) of 0.19 A ˚ for 89 Ca atom pairs. This
suggests that the unprocessed and processed ADC structures are
highly similar. Thus, in preparation for virtual screening,
unprocessed MtbADC (2C45) was modified to the processed
form, in which Ser25 was substituted with a pyruvoyl group. The
active site as well as conserved and functionally important residues
were selected by structural alignment of the processed MtbADC
with processed TthADC:fumarate and HpyADC:isoasparagine
complex structures using Multiprot [23] and visualized using
PYMOL [24]. As the active site is at a dimer interface, an
appropriate dimer was prepared. The model was further refined
by adding missing hydrogens, assigning proper bond orders, and
was submitted to a series of restrained and partial minimization
using the optimized potentials for liquid simulations all-atom
(OPLS_AA) force field [25] in the Protein Preparation Wizard of
Schro ¨dinger [26].
Structure-based virtual screening
To identify inhibitors against the above processed MtbADC,
flexible ligand based high-throughput virtual screening (HTVS)
mode of Glide 5.5 [27] was carried out using 333,761 molecules of
commercially available ligands from the Maybridge (14,400
molecules; www.maybridge.com) and Zinc [28] [zinc.docking.org,
including National Cancer Institute (hereafter NCI; 316,181
molecules) and the United States of America Foods and Drug
Administration approved drugs (hereafter FDA; 3,180 molecules)]
databases. Using the TthADC:fumarate crystal structure as a
guide, fumarate was docked with processed MtbADC and the
docking score was used as a reference to identify drug-like
inhibitors. The Maybridge, NCI and FDA molecules, as well as
fumarate, were prepared by accounting for missing hydrogens,
possible ionized states, tautomers and low energy ring conforma-
tions using the Glide LigPrep application [26].
A grid file was generated using the Receptor Grid Generation
protocol with centroid at the active site of the enzyme. A scaling
factor of 1.0 was set to van der Waals (VDW) radii for the atoms of
residues that presumably interact with ligands and the partial
atomic charge was set to less than 0.25. Ligands were then allowed
to dock with the high throughput screening (HTVS) mode and all
the obtained molecules were subjected to the Glide extra precision
(XP) mode of docking, which performs extensive sampling and
provides reasonable binding poses [27]. At this stage, ligands were
accepted only if: (i) they interacted with the residues that bind
substrate analogs in the TthADC:fumarate and HpyADC:isoas-
paragine complex structures, and (ii) the binding affinity glide
scores (G-scores) were better than the reference MtbADC:fuma-
rate score. These ligands were further assessed for their drug-like
properties based on Lipinski’s rule of five [29] and also the
absorption, distribution, metabolism, excretion and toxicity
(ADMET) properties, calculated with QikProp version 3.2
(Schro ¨dinger) [30]. In addition, the docking poses and structural
properties of some of the known ADC inhibitors, phenylhydrazine
(PubChem chemical database ID CID7516), L-cysteic acid
(CID72886), Oxaloacetate (CID164550) and D-serine
(CID71077), were compared with those of the selected drug-like
molecules. As the active site of MtbADC is located at the interface
of a dimer, the selected molecules were cross-verified by
performing virtual screening against processed monomeric ADC.
Non cross-reactivity with human pyruvoyl-dependent
enzymes
The mechanism of action of the ADC protein is similar to other
pyruvoyl dependent enzymes, such as histidine decarboxylase, S-
adenosylmethionine (SAM) decarboxylase and phosphatidyl serine
decarboxylase, which catalyze reactions utilizing the pyruvoyl
residue as a prosthetic group [17,31]. As of now, only the crystal
structure of human SAM decarboxylase (PDB id: 3H0W) [32] is
available in the PDB. In order to avoid any potential side-effect
and cross reactivity of lead molecules with SAM decarboxylase,
the inhibitors from the previous step that interacted with the
pyruvoyl group or conserved substrate binding residues Glu247,
Phe223, Phe7 or Glu67 (SAM decarboxylase numbering) were
rejected. Furthermore, the inhibitors were checked for suitable
ADMET properties and accepted.
Results
Structural overview of L-asparate a-decarboxylase
Gopalan and co-workers have solved the crystal structure of
uncleaved MtbADC (2C45) at 2.99 A ˚ resolution [13].The
structural superimposition of processed MtbADC, TthADC:fu-
marate complex and HpyADC:isoasparagine complex shows that
both substrate analogs bind to the active site (Fig. 1a), which is
formed at the interface of a dimer in a similar orientation and are
surrounded by conserved residues (Fig. 1b). The three proteins
align with pair-wise RMSDs of less than 1 A ˚. Also, the binding of
the substrate analogs to TthADC and HpyADC does not
significantly change the structure of the enzyme which is evident
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respectively. Sequence and structural analyses reveal that the
strictly conserved residues among ADCs are Lys9, His11, Tyr22,
Gly24, Pyr25, Arg54, Thr57, Tyr58, Gly73, Ala74, Ala75, Ile86
and Asn112 (MtbADC numbering). The substrate analogs interact
with Lys9*, Pyr25, Arg54*, Thr57, Tyr58 (* represents a residue
from another subunit of the dimer), where Lys 9* keeps the a-
carboxyl group of the substrate deprotonated by forming an ion
pair [15], and Pyr25 is a cofactor responsible for the activity of the
enzyme [12]. Furthermore, Arg54* contributes to substrate
specificity [15], Thr57 interacts with substrate and plays an
important role in catalysis [15] and Tyr58 acts as a proton donor
in the decarboxylation reaction [33].
Selection of inhibitors
Binding of a ligand to at least one conserved functional residue
is likely to interfere with the binding or catalysis of substrate and
would result in inhibition of the function of the protein. Out of
333,761 molecules from the three public ligand databases, 190 hits
from the Maybridge, 473 hits from NCI and 140 hits from FDA
databases were initially obtained with the high throughput virtual
screening (HTVS) mode. The ligands were allowed to bind with
processed MtbADC in the more precise Glide extra-precision
mode (Glide XP) and subsequently 28 ligands (3 Maybridge, 7
NCI and 18 FDA) with binding energy (24.9 kcal/mol or higher)
better than that for fumarate (24.2 kcal/mol) were selected. These
ligands interact with at least one of the experimentally determined
conserved functional residues (Table S1).
Of 28, seven ligands (5 FDA and 2 NCI) interact with the
MtbADC pyruvoyl group, suggesting that they could cross-react
with other pyruvoyl dependent enzymes. An assessment of cross-
reactivity of the putative inhibitors with the human SAM
decarboxylase structure, a representative of pyruvoyl dependent
enzymes, identified that only one (ZINC03871163) of the seven
molecules does not interact with any of the conserved substrate
binding residues Glu247, Phe223, Phe7 or Glu67 (SAM decarbox-
ylase numbering) or the pyruvoyl group of SAM decarboxylase.
Eight lead molecules significantly satisfy the pharmacokinetic
factors that are defined for human use and qualify as potential drug-
like molecules. They are: (2S,3R,4S,5S)-2,3,4,6-tetrahydroxy-5-
Figure 1. Conserved functional residues of ADCs that bind to substrate. (a) Stereo view of structural superimposition of processed MtbADC
(blue), processed Thermus thermophilus ADC complexed with substrate analog fumarate (red and PDB id: 2EEO) and Helicobacter pylori ADC
complexed with substrate analog isoasparagine (green, PDB id: 1UHE). The conserved and interacting residues are labeled according to MtbADC and
the interactions are shown as dashed lines. (b) Stereo view of the active site in the dimer interface. The figure was prepared using Molscript [36] and
Raster3D [37].
doi:10.1371/journal.pone.0033521.g001
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methyl) tetrahydro-2H-pyran-2,3,4,5-tetraol (ZINC03830878),
3-amino-4-(propylamino) cyclobutane-1,2-dione (LIGAND10436),
(S)-thiazolidin-3-ium-4-carboxylate (ZINC00967474), (S)-5-acet-
oxy-4-methylpentanoate (ZINC02036492), (2S,3S,4R,5R)-tetrahy-
dro-2H-pyran-2,3,4,5-tetraol (ZINC03606295), (2S,3S,4R,5S)-2,5-
bis(hydroxymethyl)tetrahydrofuran-2,3,4-triol (ZINC03830875)
and 1H-pyrazolo [3,4-d]pyrimidin-4(7H)-one (ZINC05177572).
The interacting residues for these lead molecules are shown in
Table 1 and their structures are shown in Fig. 2.
The pharmacokinetic properties of the 28 ligands were assessed
by the use of Qikprop (Table S2). The above eight lead molecules
(Table 2) fulfill drug-like properties based on Lipinski’s rule of five.
The molecular weight of the lead molecules are less than 500 kDa,
number of hydrogen bond donors is less than 5 and hydrogen
bond acceptors are less than 10. The predicted octanol/water
partition coefficient (QPlogPo/w) and aqueous solubility (QPlogS)
are in the acceptable range i.e. 22.0 to 6.5 and 26.5 to 0.5,
respectively. The predicted IC50 value for the blockage of HERG
K
+ channels (QPlogHERG) is in the acceptable range of above
25.0. The cell permeability (QPPCaco), a factor that is
responsible for drug metabolism and its access to the biological
membrane, is within the acceptable range 25 to 500. As the cell
wall of Mycobacterium tuberculosis is thicker than that of other
bacteria, the selected inhibitors must have a reasonable cell
permeability value to cross the membrane. The predicted value of
binding to human serum albumin (QPkhsa) is within the
acceptable limit 21.5 to 1.5. Absorption is one of the important
pharmacokinetic factors, especially when the most convenient way
of drug administration is oral consumption. Percentage of human
oral absorption is also within the acceptable range (,25% is poor
and .80% is high). The selected inhibitors form 2 to 5 hydrogen
bond contacts with the conserved residues of MtbADC, with glide
XP scores of 25t o26 kcal/mol, which are superior to the
24.0 kcal/mol score of fumarate. The hydrogen bond distances
range from 1.6 to 2.3 A ˚, suggesting strong ligand-MtbADC
interaction. The binding pose of the selected eight lead molecules
are illustrated in Fig. 3.
In silico validation
The reliability of the docking protocol was evaluated by
comparing the crystallographic pose of the TthADC:fumarate
complex structure with the processed MtbADC:fumarate docking
model, obtained from the Glide XP mode. The docking procedure
precisely predicted the experimental result. This indicates that the
Glide docking protocol represents nearly the same binding
conformation that is present in native crystal structure. In both
Figure 2. Chemical structures of the eight lead molecules.
ZINC03871163: (2S,3R,4S,5S)-2,3,4,6-tetrahydroxy-5-mercaptohexanal,
ZINC03830878: (2S,3S,4S,5R)-2(hydroxymethyl) tetrahydro-2H-pyran-
2,3,4,5-tetraol, LIGAND10436: 3-amino-4-(propylamino)cyclobutane-1,
2-dione, ZINC00967474: (S)-thiazolidin-3-ium-4-carboxylate, ZINC02036492:
(S)-5-acetoxy-4-methylpentanoate,ZINC03606295:(2S,3S,4R,5R)tetrahy-
dro2Hpyran2,3,4,5tetraol,ZINC03830875:(2S,3S,4R,5S)2,5bis(hydroxyme-
thyl)tetrahydrofuran-2,3,4-triol,ZINC05177572:1H-pyrazolo[3,4-d]pyrimidin-
4(7H)-one.
doi:10.1371/journal.pone.0033521.g002
Table 1. Glide extra-precision (XP) results for the eight lead molecules and fumarate by Schrodinger 9.0.
Ligand IDs
a Gscore
b Interacting amino acids
c H
d Database
e
3871163 26.05 Asn72 (1.6) Gly73(1.83) Pyr25 (2.1) Tyr22 (1.95) Arg12(1.95) 5 NCI
3830878 26.03 Asn72 (1.93) Arg54(2.27) Asn72(1.78) 2 FDA
10436 26.00 Tyr58 (1.88) Gly73 (1.69) Asn72 (1.76) 3 Maybridge
967474 25.42 Tyr58 (1.8) Asn72(1.6) 2F D A
2036492 25.29 Thr57(1.8) Tyr58 (2.1) Lys9(2.1) 3 NCI
3606295 25.11 Arg54 (2.12) Thr57 (1.74) Tyr58 (2.1) Asn72 (1.67) Gly73 (1.69) 5 FDA
3830875 24.97 Arg54(2.3) Thr57 (2.29) Asn72 (2.25) Asn72 (1.74) 3 FDA
5177572 24.96 Asn72 (1.7) Tyr58 (2.1) Arg54 (2.0) 3 FDA
Fumarate 24.20 Thr57(1.7) Lys9(2.34) Tyr58 (1.60) Arg54(2.16) 4
aThe ids of the lead molecules.
bGlide extra precision scores (kcal/mol).
cThe residues interacting with the lead molecules. The value in bracket represents the hydrogen bond distance between the atoms of respective residues, in angstrom
(Au).
dH represents the number of hydrogen bond.
eThe ligand belong to the corresponding chemical database.
doi:10.1371/journal.pone.0033521.t001
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residues, Lys9*, Arg54*, Thr57 and Tyr58 (Fig. S2).
The ADC active site is formed by the interface of a dimer, with
relatively small volume. This cleft can support only molecules of
relatively small size [34]. The reliability of the identified drug-like
lead molecules is justified by the fact that they are small in size,
when compared to some known ADC inhibitors (Figs. S3 and S4).
To further support our results, fumarate was docked with the
MtbADC monomer and dimer. It binds to the ADC monomer
with 21.5 kcal/mol glide score, whereas docking to the ADC
dimer gives a Gscore of 24.2 kcal/mol in the Glide XP mode.
This clearly underlines the fact that the active site, formed by the
dimer interface, favors the binding of only small ligands.
Furthermore, the conserved functional residue Arg54, which is
responsible for substrate specificity [15], is brought to the
proximity of the substrate binding site only in the dimeric
conformation. Our results were cross checked with the binding
modes of the known ADC inhibitors, which were modeled using
docking studies. These inhibitors bind to the same site as fumarate
and isoasparagine, and interact with at least one of the conserved
experimentally determined functional residues (Table S3 and Fig.
S5). In vitro experimental verification of the 28 inhibitors of Table
S1 and the inhibitors reported in the literature are underway
(unpublished data). Furthermore, shortlisted inhibitors will be
verified in Mycobacterium tuberculosis culture using established
techniques and a latest protocol [35].
Discussion
The present work identifies eight drug-like lead molecules, from
three available public ligand databases, that interact with the
known functionally conserved residues of aspartate a- decarbox-
ylase. These residues have experimentally been shown to interact
with substrate analogs fumarate and isoasparagine. In addition,
the lack of cross-reactivity of these inhibitors with pyruvoyl
dependent S-adenosylmethionine (SAM) decarboxylase suggests
that these lead molecules can be potential selective drug-like
inhibitors of MtbADC. Our findings are consistent with known
experimental results and support the idea that the active site is at
the dimer interface for substrate or inhibitor specificity. The
backbone scaffolds of the identified eight drug-like molecules can
provide suitable platforms for the development of potential
therapeutics, after adequate experimental follow up, in the
treatment of tuberculosis.
The exact role of the conserved residue Tyr22 in catalysis is not
clear as its flexible side chain is not oriented towards the substrate
analog in the HpyADC:isoasparagine [15] complex. However, it
binds to fumarate in the TthADC:fumarate complex structure. To
understand its role, an alternate rotamer was chosen in our
chemoinformatics approach by placing it towards the active site,
mimicking the TthADC:fumarate complex structure. To our
surprise, the glide score was better with 25.27 kcal/mol (instead
of 24.2 kcal/mol), representing a favorable binding mode. The
analysis of this binding pose suggests the interaction of ligands with
Tyr22 may follow the TthADC:fumarate complex structure.
However, this is in contrast to the HpyADC:isoasparagine
complex structure, where Tyr22 does not interact with the
substrate analog. Hence, the role of Tyr22 needs to be further
verified with additional mutational, structural and biochemical
experiments.
The central dogma for the identification of new anti-TB drugs is
that the inhibitors should be active against both latent (or
dormant) and non-dormant bacilli. Mtb, as a pathogen, has
evolved to exploit dormancy or latency to its advantage. Since
most of the current drugs target the rapidly growing organism, the
current drug regimens in the treatment of this infection tend to be
of extraordinarily long durations, which lead to tremendous
problems, like patient noncompliance and development of MDR
strains. This is where the uniqueness of targeting ADC as a drug
target may be of considerable importance. An inhibitor or drug
that is developed against ADC could be used in conjunction with
conventional antibiotics. This combined attack can shorten the
time frame of the current therapy and help for an effective
clearance of the bacterium from patients.
Table 2. Assessment of drug-like properties of the lead molecules and fumarate as verified by Qikprop (Schrodinger 9.0).
Ligand IDs
a MW
b HD
c HA
d QPlogPo/w
e QPlogS
f QPlogHERG
g QPPCaco
h
Percent human
oral absorption
i QPlogKhsa
j
3871163 196.2 3.8 8.3 21.3 20.4 22.9 89.1 54.2 21.1
3830878 180.2 5.0 8.3 21.7 20.8 22.5 106.9 53.3 20.9
10436 154.2 3.0 6.0 20.9 21.1 23.3 125.6 59.5 20.8
967474 133.2 2.0 4.0 22.0 20.4 21.4 41.9 44.1 20.9
2036492 174.2 1.0 4.0 1.2 21.7 21.5 74.8 67.7 20.7
3606295 150.1 4.0 8.5 21.7 20.9 22.1 192.4 57.7 20.8
3830875 180.2 5.0 8.3 21.7 20.7 22.7 106.4 53.3 20.9
5177572 136.1 2.0 4.5 20.6 22.3 22.9 166.7 63.5 20.7
Fumarate 114.1 2.0 4.0 20.3 20.2 0.8 4.1 36.5 21.2
aLigand IDs are of the Maybridge, NCI, FDA ligand databases.
bMolecular weight (,500 Da).
cHydrogen bond donors (,5).
dHydrogen bond acceptors (,10).
ePredicted octanol/water partition co-efficient log p (recommended range: 22.0 to 6.5).
fPredicted aqueous solubility; S in mol/L (acceptable range: 26.5 to 0.5).
gPredicted IC50 value for blockage of HERG K+ channels (acceptable range: above 25.0).
hPredicted Caco-2 cell permeability in nm/s (acceptable range: 25 is poor and .500 is great).
iPercentage of human oral absorption (,25% is poor and .80% is high).
jPrediction of binding to human serum albumin (acceptable range: 21.5 to 1.5).
doi:10.1371/journal.pone.0033521.t002
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Figure S1 Pantothenate and CoA biosynthesis pathway.
L-Aspartate a-decarboxylase (ADC) catalyzes the decarboxylation
of L-aspartate to b-alanine.
(TIFF)
Figure S2 Fumarate binding in ADC. (a) The superimposed
view of the TthADC:fumarate crystal structure (red) and
MtbADC:fumarate docking model (blue) is shown. The processed
model for MtbADC was generated from the crystal structure of
unprocessed protein and docking of fumarate was achieved using
the Glide Extra Precision mode. The interacting conserved
residues are labelled for MtbADC and the interactions between
the protein and fumarate are shown as dashed lines in the
corresponding colors. (b) Surface diagram around the substrate
binding cavity in the same orientation of panel A. The interacting
protein residues are also shown in faint trace.
(TIFF)
Figure S3 The structures of known and reported
inhibitors against ADC.
(TIFF)
Figure S4 Ligands docked to monomeric MtbADC. The
structures of the top three hits, obtained by docking the Maybridge,
NCI and FDA databases with the processed monomeric MtbADC
structure. These molecules are big and cannot be genuine inhibitors as
Figure 3. Binding poses of the identified eight lead molecules with MtbADC. The binding modes of the proposed lead molecules are
shown as ball and stick. Atoms colors are: H: white, C: green, N: blue, O: red and S: yellow. The interacting MtbADC residues are drawn as thin
wireframe in the same color scheme and are labeled. Hydrogen bond interactions are shown as dotted yellow lines, along with the distance between
donor and acceptor atoms. The binding pose of protein:lead molecule interactions were generated with the Maestro program in the Schrodinger
software suite.
doi:10.1371/journal.pone.0033521.g003
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smaller volume and only molecules of small size can bind in the pocket.
(TIFF)
Figure S5 Binding poses of known inhibitors/ligands.
The known inhibitors or ligands are shown as thick ball and stick.
Atoms are colored as: H: white, C: green, N: blue, O: red and S:
yellow. The interacting MtbADC residues are drawn as thin
wireframe with the same color scheme and are labeled. Hydrogen
bond interactions are shown as dotted yellow lines, along with the
distance between donor and acceptor atoms.
(TIFF)
Table S1 The 28 ligand hits from the Maybridge, NCI
and FDA databases which interact with at least one of
the conserved functional residues of MtbADC residues
involved in substrate binding and their glide score
(kcal/mol). The ligands are ranked according to their glide
scores in their respective databases. The ligands that interact with
Pyr25 are in bold. The entries of Table 1 are underlined.
(DOCX)
Table S2 The ADMET properties of the 28 ligands. The
ligands that interact with Pyr25 are in bold. The entries of Table 2
are underlined. The definitions of the properties are as in Table 2.
(DOCX)
Table S3 Interactions of selected known inhibitors/
ligands with MtbADC as verified by Glide XP.
(DOCX)
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